StockNews.com Begins Coverage on FibroGen (NASDAQ:FGEN)

StockNews.com assumed coverage on shares of FibroGen (NASDAQ:FGEN - Free Report) in a research report report published on Friday morning. The firm issued a hold rating on the biopharmaceutical company's stock.

A number of other equities analysts have also commented on FGEN. William Blair reaffirmed a "market perform" rating on shares of FibroGen in a research report on Wednesday, November 13th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of FibroGen in a research report on Thursday.

FibroGen Trading Down 17.8 %

Shares of NASDAQ FGEN traded down $0.13 during mid-day trading on Friday, reaching $0.58. The company had a trading volume of 4,496,465 shares, compared to its average volume of 4,876,516. The stock has a market cap of $58.47 million, a price-to-earnings ratio of -0.47 and a beta of 0.75. FibroGen has a 52 week low of $0.18 and a 52 week high of $2.80. The business's 50-day moving average is $0.53 and its 200-day moving average is $0.43.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in FGEN. Geode Capital Management LLC boosted its stake in shares of FibroGen by 3.1% during the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company's stock valued at $433,000 after purchasing an additional 32,884 shares in the last quarter. JPMorgan Chase & Co. boosted its position in FibroGen by 430.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company's stock valued at $668,000 after acquiring an additional 1,358,194 shares in the last quarter. FMR LLC increased its holdings in shares of FibroGen by 21.8% in the 3rd quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company's stock valued at $153,000 after acquiring an additional 68,569 shares during the period. Franklin Street Advisors Inc. NC raised its position in shares of FibroGen by 100.0% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company's stock worth $106,000 after acquiring an additional 100,000 shares in the last quarter. Finally, Assenagon Asset Management S.A. purchased a new stake in shares of FibroGen during the 3rd quarter worth $307,000. Hedge funds and other institutional investors own 72.71% of the company's stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.